Cimzia vs Entyvio for Crohn's Disease: A Comparison

Cimzia and Entyvio take very different mechanistic approaches to moderate-to-severe Crohn's disease. Cimzia (certolizumab pegol) is a subcutaneous anti-TNF biologic. Entyvio (vedolizumab) is a gut-selective biologic. Patients comparing these drugs often weigh a systemic anti-TNF approach against a gut-targeted strategy with a favorable systemic safety profile. This guide walks through the cimzia vs entyvio crohn's comparison.

Anti-TNF vs Gut-Selective Mechanism

Cimzia binds TNF-alpha and reduces inflammation throughout the body and in the gut. Entyvio binds the alpha-4-beta-7 integrin, a receptor found almost exclusively on gut-homing lymphocytes. By blocking these immune cells from entering inflamed intestinal tissue, Entyvio quiets Crohn's inflammation without meaningfully suppressing the immune system elsewhere. The certolizumab vs vedolizumab distinction shapes speed of onset, safety profile, and long-term convenience.

Efficacy in Crohn's

Cimzia's Crohn's efficacy rests on PRECISE-1 and PRECISE-2, which showed significant clinical response and remission benefits over placebo in biologic-naive and biologic-experienced patients. Entyvio's Crohn's efficacy was established in GEMINI 2 and GEMINI 3. GEMINI 2 showed vedolizumab superior to placebo on clinical remission at week 6 and week 52, though with slower onset than anti-TNFs. No head-to-head trial has directly compared Cimzia with Entyvio in Crohn's. Indirect comparisons suggest Cimzia offers faster clinical response, while Entyvio offers strong maintenance efficacy with a distinctive safety profile.

Onset of Action

Cimzia produces meaningful Crohn's response by week 6 based on PRECISE. Entyvio's onset is slower in Crohn's, with meaningful response often not evident until week 10 to 14 and continued improvement through week 52. For Crohn's patients with active symptoms who cannot tolerate a long ramp-up, Cimzia's faster onset is an advantage. For patients in less acute states or those prioritizing the narrowest systemic immune footprint, Entyvio's slower onset is generally manageable with supportive care.

Safety and Infection Risk

Cimzia carries anti-TNF class risks including serious infections, reactivation of latent TB or hepatitis B, and a small increase in lymphoma risk. Entyvio's gut-selective action produces very low rates of systemic infection, and its long-term safety data is among the cleanest of any IBD biologic for non-GI infections. A 2024 Swedish registry study flagged a higher rate of serious gastrointestinal infections on vedolizumab compared with anti-TNFs, though overall systemic infection risk was lower. For anti-TNF vs gut-selective crohn's safety, patients with infection concerns, cancer history, or comorbidities often find Entyvio's narrower mechanism more reassuring.

Administration and Dosing

Cimzia for Crohn's uses 400 mg SC at weeks 0, 2, and 4 for induction, then 400 mg every 4 weeks for maintenance, per UCB's prescribing information. Entyvio starts with three 300 mg IV infusions at weeks 0, 2, and 6, followed by maintenance every 8 weeks. After IV induction, Entyvio patients who respond can switch to a 108 mg SC pen every 2 weeks, according to Takeda's dosing information. For Crohn's patients comparing administration, Cimzia is all-SC throughout. Entyvio requires IV induction but offers SC or IV maintenance. Cimzia's every-4-week maintenance is between Entyvio's every-8-week IV cadence and its every-2-week SC option.

Fistulizing Crohn's

For fistulizing Crohn's complications, anti-TNFs including Cimzia have the strongest trial data, particularly drawing on Remicade's ACCENT II precedent for the class. Entyvio's fistulizing data is more limited and does not consistently show the same perianal fistula outcomes as anti-TNFs. For Crohn's patients with significant perianal disease, Cimzia is often preferred over Entyvio based on mechanism class considerations.

Safety for Extraintestinal Manifestations

Crohn's patients with extraintestinal manifestations (joint involvement, skin, eye) may respond better to systemic anti-TNFs like Cimzia, which treat these manifestations alongside intestinal disease. Entyvio's gut-selective action does not effectively treat extraintestinal manifestations, which may limit its utility in patients with significant systemic inflammatory involvement.

Pregnancy Considerations

Cimzia's lack of an Fc region minimizes active placental transfer during pregnancy, making it an option for pregnant patients needing to maintain biologic therapy through delivery. Entyvio undergoes active placental transfer via FcRn like other IgG biologics, with measurable infant drug levels at birth. For Crohn's patients who are pregnant or planning pregnancy, Cimzia's pregnancy profile is often preferred over Entyvio.

Choosing With Your GI

For a Crohn's patient deciding between Cimzia and Entyvio, Cimzia tends to win on speed of onset, fistulizing disease outcomes, extraintestinal manifestation coverage, and pregnancy considerations. Entyvio tends to win on the narrowest systemic safety footprint and established long-term safety data. Your GI will weigh disease severity, presence of perianal disease or fistulas, extraintestinal manifestations, pregnancy plans, and insurance coverage. A log of stool frequency, urgency, abdominal pain, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.